Publication:
Small cell carcinoma of the prostate: Molecular basis and clinical implications

Simple item page
dc.contributor.authorWang, Lisha
dc.contributor.authorDavidson, Darrell D.
dc.contributor.authorMontironi, Rodolfo
dc.contributor.authorLopez-Beltran, Antonio
dc.contributor.authorZhang, Shaobo
dc.contributor.authorWilliamson, Sean R.
dc.contributor.authorMacLennan, Gregory T.
dc.contributor.authorWang, Chaofu
dc.contributor.authorWang, Mingsheng
dc.contributor.authorEmerson, Robert E.
dc.contributor.authorDu, Xiang
dc.contributor.authorCheng, Liang
dc.date.accessioned2020-03-26T11:54:04Z
dc.date.available2020-03-26T11:54:04Z
dc.date.issued2015
dc.description.abstractSmall cell carcinoma of the prostate (PSCC) is a rare and highly aggressive malignancy with a dismal prognosis. Most patients present with advanced disease, including metastases to bone, viscera, and the central nervous system. Histologically, PSCC is indistinguishable from its pulmonary counterpart. Although PSCC may occur in pure form, as in small cell lung carcinoma, it also occurs in conjunction with conventional glandular prostate carcinoma, and may evolve from conventional adenocarcinoma during the course of hormonal therapy. Immunohistochemical staining is extremely helpful in establishing the diagnosis, a prerequisite, as in small cell lung cancer, for optimal therapeutic strategy. Currently, combinations of surgical resection, chemotherapy, and radiation therapy represent the main treatment options. Improvement in survival may depend upon the identification of new molecular markers to facilitate earlier diagnosis and the development of novel targeted therapies. This review will discuss general aspects of PSCC, focusing on ways in which our understanding of PSCC has been advanced by studies of the histopathologic, immunohistochemical and molecular alterations in this disease.es
dc.formatapplication/pdfes
dc.format.extent12es
dc.identifier.citationHistology and Histopathology, Vol. 30, n.º 4 (2015)
dc.identifier.doihttps://doi.org/10.14670/HH-30.413
dc.identifier.issn1699-5848
dc.identifier.issn0213-3911
dc.identifier.urihttp://hdl.handle.net/10201/88726
dc.languageenges
dc.publisherF. Hernández y Juan F. Madrid. Universidad de Murcia: Departamento de Biología Celular e Histologíaes
dc.rightsinfo:eu-repo/semantics/openAccesses
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectProstatic small cell carcinomaes
dc.subjectAndrogen receptores
dc.subjectTMPRSS2-ERG rearrangementes
dc.subjectClonal origines
dc.subject.otherCDU::5 - Ciencias puras y naturales::57 - Biología::576 - Biología celular y subcelular. Citologíaes
dc.titleSmall cell carcinoma of the prostate: Molecular basis and clinical implicationses
dc.typeinfo:eu-repo/semantics/articlees
dspace.entity.typePublicationes
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Wang-30-413-424-2015.pdf
Size:
5.3 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.39 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Histology and histopathology Vol.30, nº4 (2015)